similarly confirmed that stroke treatment with tPA is effective in community practice in Canada. 12, 13 Roughly 40,000 Canadians have an ischemic stroke each year and less than 6% get treated with tPA. 5, [14] [15] [16] This low percentage is partially because of the strict inclusion criteria required for administration of tPA, particularly the short time window, and partly because of lack of protocols and processes to expedite acute stroke care. Because the public may not recognize stroke symptoms, 17, 18 measures are being taken to improve awareness and rapid response. 19, 20 Symptomatic intracerebral hemorrhage (ICH) is the most devastating of the complications associated with use of tPA for AIS. Hemorrhage rates are highest when the protocol is not followed 21 and drop dramatically when thrombolysis is given strictly within the recommended therapeutic window, and when no contraindications are present. 22, 23 Since licensure of tPA, changes in practice have occurred. In this paper, we summarize current data on the safety and effectiveness of stroke thrombolysis from phases 1 and 2 of the Registry of the Canadian Stroke Network (RCSN).
METHODS
The RCSN is a comprehensive, prospective registry of consecutive stroke patients from across Canada, established in order to provide a picture of stroke care in the nation. The registry contains detailed records ranging from baseline to outcome information. The RCSN has been divided into three phases, of which phase 1 (June 2001 to February 2002) and phase 2 (June 2002 to December 2002) are analyzed in this study. Data were collected for all stroke types, from stroke centres in eight provinces (21 hospitals in phase 1, 25 in phase 2), with an estimated 20% of all stroke care in the country being provided at these institutions. 24 The first two phases in the registry were limited to about 40% of the eligible patients, as signed informed consent was required. 25 Data were extracted from the RCSN phase 1 and 2 for all patients presenting with AIS treated with tPA. Patients with transient ischemic attack, subarachnoid hemorrhage or intracerebral hemorrhage were excluded. Demographics, clinical data including the administration of tPA, process measures, and outcome were analyzed. Protocol violations were defined as use of tPA in the presence of suspected subarachnoid hemorrhage, INR>1.7, blood pressure>185/110, non-ischemic stroke, PTT>40, glucose <3 or >22 mM, platelet count less than 100 x 10 9 cells per litre, seizure at onset, and symptom onset to hospital arrival time greater than three hours. We used three measures of baseline stroke severity: the Glasgow Coma Scale; the Canadian Neurological Scale (CNS); and the National Institutes of Health Stroke Scale (NIHSS). Secondary symptomatic ICH was defined by the appearance of hemorrhage on the second imaging scan plus neurological worsening.
The primary outcomes were in-hospital mortality, symptomatic ICH and Stroke Impact Scale-16 (SIS-16) at sixmonths. 26, 27 A good outcome was defined as a score ≥75 on the SIS-16, meaning high physical function with a slight disability. 26 Secondary outcomes included interval times, discharge disposition, the presence of a neurological deficit at discharge, length of hospitalization, and in-hospital complications. Complications such as cardiac arrest, myocardial infarction, decubitis ulcer, deep vein thrombosis, pneumonia, pulmonary embolism, urinary tract infection, falls, and depression were grouped as non-neurological complications.
Statistical Methods
The data are reported using standard descriptive statistics. Appropriate parametric (t-test) or non-parametric (MannWhitney-U, Kruskal-Wallis) tests were applied depending upon the distribution of each particular variable. Proportions were compared using a Chi-square test. Logistic regression provided adjusted estimates for binary outcomes. General linear modeling was used to estimate predictors of outcome on the SIS-16 scale. All multivariable models were developed using a backwards elimination procedure and the threshold significance level to keep a variable was 0.10. Analyses were performed using SAS 8.2.
RESULTS

Description of the Cohort
A total of 6091 patients were diagnosed with stroke in phase 1 and 2 of the RCSN, of which 4107 (67.4%) had ischemic stroke. Of these, 366 (8.9%) were treated with tPA. More patients were given tPA in phase 2 (10.2%) than in phase 1 (7.9%). Ultimately, 242 (66.1%) patients provided informed consent to full participation in the RCSN, with detailed baseline data collection and six month follow-up interviews; for the remainder of patients, only a minimal data set could be collected. There was no difference in age, gender, median CNS score, level of consciousness, stroke subtype, median time intervals or length of hospitalization between patients who did not consent compared to consented patients. However, patients who did not consent were more likely to have more severe stroke (75.0% vs. 70.9% with CNS score ≤7, p=0.045) and were more likely to die in hospital (21.3% vs. 11.6%, p=0.018). 25 In-hospital mortality among all patients who received tPA, regardless of consent, was 14.6%. For clarity's sake, we will not discuss unconsented tPA patients further.
Baseline Characteristics
Patients who were given tPA had a median age of 71. [ Table  1 ]. Male sex (58.7%), right-handedness (71.8%) and Caucasian race (87.9%) were predominant. Hypertension was the dominant risk factor and half of the patients had a clinical total anterior circulation syndrome. A large majority (85.8%) of patients were treated with intravenous (IV) tPA. The median dose of tPA given was 63mg (IQR 53.5-72.5) for IV patients, and 20mg (IQR 7-50) for intra-arterial (IA) patients.
Process Measures
Only 66.9% of patients treated with tPA had a code stroke protocol activated, meaning a stroke emergency was declared by the paramedics. This warranted prompt communication with and transportation to a hospital with stroke care resources to determine if the patient was a candidate for an acute stroke intervention using standard orders [ There was a significant inverse relationship between lastseen-normal-to-ER time versus ER-to-treatment time (p<0.0001)
[ Figure] . This was driven by the computed tomography (CT)-totreatment time (p< 0.0001), and not ER-to-CT time (p=0.415) and stroke severity did not confound this relationship. The Pearson correlation coefficients between time points are: lastseen-normal-to-ER and ER-to-treatment r=-0.39 (p<0.0001, n=121); last-seen-normal-to-ER and CT-to-treatment r=-0.32 (p<0.0001, n=121); CT-to-treatment and ER-to-treatment=0.76 (p<0.0001, n=121).
Of all consented patients with AIS, 32.4% (720/2220) were candidates for tPA based on time since stroke onset less than 150 minutes, yet only 25.5% (183/719) of these candidates received thrombolysis. The most prominent reasons for no treatment were that the deficit was deemed too mild in 196/536 patients (36.6%), and rapid improvement was observed in 161/536 patients (30.0%). Of the AIS patients who did not arrive at the hospital within 150 minutes of stroke onset, 2.7% (41/1493) were thrombolysed. Among these 41 patients, 30 (73.2%) were treated with IV tPA, nine (22.0%) were treated intra-arterially (IA), one (2.4%) was treated IV/IA and one patient did not have the method of tPA administration recorded. Protocol violations occurred in 27.7% (67/242) of patients who received tPA, with 14.9% (10/67) mortality [ Table 3 ]. However, protocol violation was not associated with increased mortality or symptomatic ICH.
Outcome
In the subgroup of tPA patients in the RCSN, in-hospital mortality was 11.6%. The CNS score (odds ratio=0.68 per unit increase, 95%CI 0.54-0.85, p=0.001) and glucose level (odds ratio=1.24 per mmol increase, 95%CI 1.07-1.44, p=0.005), but not age, gender or treatment time, were predictive of in-hospital mortality. At the time of discharge, 82.9% had a residual neurological deficit. In phase 2 (n=116), the symptomatic ICH rate was 4.3% (95%CI: 0.6%-8.0%) [ Table 4 ].
Of the 242 consented tPA patients, 142 patients had their SIS-16 scores recorded at six months, but the patients who were missing this data did not differ on baseline variables. The mean SIS-16 score was 73.2, and the percentage of patients having a score above 75 points was 62.0%. In a multivariable model, age (p=0.013) and CNS score (p<0.001) were the only predictors of SIS-16. Outcome did not vary by onset-to-ER time or gender.
DISCUSSION
Overall 8.9% of patients with AIS were treated with tPA in phase 1 and 2 of the RCSN. The proportion treated increased from phase 1 to phase 2 of the registry, which demonstrates an upward trend of acceptance of thrombolysis with time. This is higher than the international average, 16, 21, 28, 29 and suggests that at RCSN hospitals stroke thrombolysis is becoming the accepted standard.
Of consented AIS patients in phase 1 and 2 of the RCSN, only 32.4% were candidates for tPA based on an onset-to-ER time less than 150 minutes, suggesting that the time from stroke onset to emergency arrival remains a very important barrier to thrombolysis delivery. Of these potentially eligible patients, only 25.5% were treated. So few patients were treated because the majority were considered too mild to warrant treatment or were improving rapidly. Patients with rapidly improving or mild symptoms warrant careful assessment because a third of such patients have poor outcomes. 15 Intra-arterial (IA) and combined IV/IA therapies have been studied in acute stroke. [30] [31] [32] In this cohort, tPA was given strictly IA 9.0% of the time, and 5.2% IV/IA. Despite the lack of efficacy trials, these alternate approaches are being put into practice in Canada.
Outcome of tPA patients is improved if treatment is initiated rapidly. The guideline endorsed by NINDS for ER-to-CT time is 25 minutes, and 60 minutes for ER-to-treatment time. 33 In our study only 28.3% of patients were treated with an ER-totreatment time of less than 60 minutes. A significant negative relationship exists between last-seen-normal-to-ER arrival time and ER-to-treatment time. The patients received tPA much sooner after their CT scan if they arrived late in the time window. This has been previously reported, 7, 11 and indicates that patients arriving early to the ER are not receiving the benefits of expedited treatment.
Safety outcomes were consistent with results from the major randomized trials of tPA. 2, 11, 12 There was a low reported symptomatic ICH rate among tPA patients of 4.3%.
Patients in our study had a mean SIS- scale score of 2. 26 Predictors of SIS-16 were age and stroke severity. Gender was not a predictive factor. Women tend to do worse in the acute phase after stroke, with a longer hospital stay and more severe stroke. [34] [35] [36] [37] However, women who are treated with tPA for AIS benefit more than men 38 because treatment nullifies this sex-based difference. Since all patients were treated in our cohort, outcome (both mortality and SIS-16) did not differ by gender. This study has notable limitations. There are comparatively few patients in this study (n=242), in large part due to selection bias induced by the consent-based approach. 25 This will not be an issue for the ongoing phase 3 of the RCSN as the Ethics Review Boards of the participating hospitals have permitted data collection without patient consent. Another limitation is that all data were from highly specialized institutions, 24 which may have decreased mortality and improved outcome from the actual population. This implies that our results may not be fully generalizable to the average community hospital.
Stroke is an increasingly treatable illness, and with the advent of integrated "stroke teams" in Canada, stroke care is improving. Thrombolysis is a vital part of the system of stroke care and continues to be safe and effective in Canada.
APPENDIX
The following institutions participated in the Registry of the Canadian Stroke Network Phase I & Phase II:
Queen Elizabeth II Health Sciences Centre, Halifax, Nova
